You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Musculoskeletal conditions
  5. Arthritis

Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed

  • Technology appraisal guidance
  • Reference number: TA715
  • Published:  14 July 2021
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Resource impact
  2. Guidance into practice

Tools and resources

Tools to help you put the guidance into practice.

Resource impact

  • Research impact report (PDF 228 KB)

    Published:
    14 July 2021
  • Resource impact template (Excel 1.35 MB)

    Published:
    14 July 2021

Guidance into practice

  • About the Into practice guide

  • Practical steps to improving the quality of care and services using NICE guidance

Back to top